<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762017</url>
  </required_header>
  <id_info>
    <org_study_id>ACT-01_P2_01</org_study_id>
    <secondary_id>2020-003147-29</secondary_id>
    <nct_id>NCT04762017</nct_id>
  </id_info>
  <brief_title>ACT-01 in Patients With Acute Optic Neuritis</brief_title>
  <acronym>ACUITY</acronym>
  <official_title>A Two-arm, Randomized, Double-blind, Placebocontrolled, Monocentric Study to Evaluate the Safety and Tolerability of ACT-01 Compared to Placebo in Patients With Acute Optic Neuritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accure Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurotrials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Accure Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of ACT-01 compared to placebo in patients with acute&#xD;
      optic neuritis (AON) receiving the standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ACUITY is a phase 2a, monocentric, two-arm, randomised, double-blind, placebo-controlled&#xD;
      study to evaluate the safety and tolerability of ACT-01 compared to placebo in patients with&#xD;
      acute optic neuritis (AON) receiving the standard of care. Thirty-six eligible subjects aged&#xD;
      18 to 60, with recent onset (visual loss symptoms) of unilateral AON (idiopathic or&#xD;
      associated with multiple sclerosis) will be randomized to receive ACT-01 or placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">December 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: adverse events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>To determine if ACT-01 treatment is associated within increase of adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Change in ganglion cell and inner plexiform layer thickness in the affected eye measured with optical coherence tomography (OCT) compared to baseline in the affected eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Change in Retinal Nerve Fibre Layer thickness in the affected eye measured with OCT compared to baseline in the affected eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Change on the 2.5% Early Treatment Diabetic retinopathy study (ETDRS) Low Contrast Letter Acuity chart and ETDRS high contrast visual acuity measured in the affected eye compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Optic Neuritis</condition>
  <condition>Optic; Neuritis, With Demyelination</condition>
  <arm_group>
    <arm_group_label>Multidose ACT-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily IV infusions of ACT-01 (n=18) for 5 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily IV infusions of Placebo (n=18) for 5 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-01 IV administration</intervention_name>
    <description>Multiple Dose of ACT-01 IV administration for 5 consecutive days</description>
    <arm_group_label>Multidose ACT-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo IV administration</intervention_name>
    <description>Placebo IV administration for 5 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with a unilateral acute optic neuritis with a demyelinating origin&#xD;
&#xD;
          -  Onset of visual loss symptoms in the last 10 days before randomization&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Optic neuropathy of non-demyelinating origin&#xD;
&#xD;
          -  Known Neuromyelitis optica with autoantibodies against aquaporin-4 (AQP4-Abs)&#xD;
&#xD;
          -  Patients with widespread and symmetric white matter alterations in the screening MRI&#xD;
             suggestive of other demyelinating disorders (e.g. metabolic disorders, mitochondrial&#xD;
             disorders)&#xD;
&#xD;
          -  Active, chronic disease (or stable but treated with immune therapy) of the immune&#xD;
             system other than MOG antibody associated disorder (MOGAD) or Multiple Sclerosis (MS)&#xD;
             (e.g. Sjögren's disease, systemic lupus erythematosus) or with a known&#xD;
             immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune&#xD;
             deficiency)&#xD;
&#xD;
          -  An alternative cause of visual loss (e.g. compressive or infiltrative lesion of the&#xD;
             optic nerve, infections, genetic forms of visual loss.&#xD;
&#xD;
          -  Diagnosed with macular oedema, severe myopia (&gt;6 δ) or other disease of the retina at&#xD;
             inclusion&#xD;
&#xD;
          -  Known diabetic retinopathy&#xD;
&#xD;
          -  Known glaucoma&#xD;
&#xD;
          -  Female patients of child-bearing potential who are unwilling to use an effective&#xD;
             contraception while enrolled on study and for the duration of the study.&#xD;
&#xD;
          -  Male patients not willing to use contraception (abstinence, condom etc..) while&#xD;
             enrolled in the study and receiving the experimental drug, and for at least 2 days&#xD;
             after the last experimental drug administration.&#xD;
&#xD;
          -  Breastfeeding or pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rossella Medori, MD</last_name>
    <role>Study Director</role>
    <affiliation>Accure Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Thibault, MSc</last_name>
    <email>jennifer.thibault@icm-institute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>STEPHANE PARIS, MSc</last_name>
    <email>sparis@accure.health</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIC Neurosciences - La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Optic Neuritis (AON)</keyword>
  <keyword>Demyelination</keyword>
  <keyword>Optic Neuritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

